 Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 | | 1998 | 0 | 3 | 3 | | 1999 | 0 | 3 | 3 | | 2000 | 1 | 2 | 3 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 4 | 4 | | 2004 | 1 | 1 | 2 | | 2005 | 3 | 4 | 7 | | 2006 | 0 | 3 | 3 | | 2007 | 6 | 11 | 17 | | 2008 | 5 | 4 | 9 | | 2009 | 6 | 5 | 11 | | 2010 | 9 | 13 | 22 | | 2011 | 4 | 13 | 17 | | 2012 | 6 | 14 | 20 | | 2013 | 10 | 15 | 25 | | 2014 | 12 | 11 | 23 | | 2015 | 11 | 16 | 27 | | 2016 | 15 | 30 | 45 | | 2017 | 16 | 21 | 37 | | 2018 | 17 | 25 | 42 | | 2019 | 19 | 11 | 30 | | 2020 | 11 | 15 | 26 | | 2021 | 14 | 11 | 25 | | 2022 | 4 | 8 | 12 | | 2023 | 1 | 8 | 9 | | 2024 | 14 | 13 | 27 | | 2025 | 18 | 22 | 40 | | 2026 | 6 | 3 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Figueroa V, Coianis MI, Sahores A, Pataccini G, Abba MC, Elía A, May M, Vanzulli SI, Martínez Vázquez P, Burruchaga J, Torres F, Sartorius CA, Lanari C, Lamb CA. Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer. Br J Cancer. 2026 Jun; 134(11):1671-1682.
-
Hinz TK, Le AT, Doan T, Ast A, Jaramillo S, Avila JT, Skhisov D, Haines S, Navarro AC, Patil T, Nemenoff RA, Heasley LE. Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma. Cancer Lett. 2026 Jun 28; 648:218467.
-
Waliany S, Cooper AJ, Liu SV, Gautschi O, Rotow JK, Smith KER, Weber UM, Lee DH, Loong HHF, Patel JD, Pennell NA, Nagasaka M, Patel SA, Tan DSW, Solomon BJ, Kim TM, Pall G, Riess JW, Sun L, Früh M, Uy NF, Gadgeel S, Feng J, Do A, Falcon C, Leighl NB, Baik CS, Lai GGY, Ou SI, Cheung KSY, Patil T, Mansfield AS, Weiler D, Yeap BY, Wirth LJ, Gainor JF, Drilon A, Lin JJ. Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium. Clin Cancer Res. 2026 Mar 16; 32(6):1157-1168.
-
Lerman BJ, King M, Mody R, Onyeama SJ, Marachelian A, Cash T, Federico SM, Granger M, Desai AV, Shusterman S, Foster JH, Sokol E, Greer C, Streby K, Meany HJ, Vo KT, Macy ME, Bagatell R. Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study. Pediatr Blood Cancer. 2026 May; 73(5):e70195.
-
Morgenstern DA, Barone G, Corradini N, Federico SM, Flotho C, Gerber NU, Khaw SL, Macy ME, Place AE, Vo KT, Badawi M, Chen X, Luo A, Rocco MA, Ross JA, Scherer F, Sunkersett G, Onishi M, Goldsmith KC. Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study. Pediatr Blood Cancer. 2026 May; 73(5):e70178.
-
Collier AE, Hilz S, Chibly AM, Duan C, Pasquina LW, Sun X, Chavez-MacGregor M, Bardia A, Martín M, Lim E, Sohn J, Pérez-Moreno PD, Fernando TM, Moore HM. ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer. Nat Commun. 2026 Mar 12; 17(1).
-
Shao C, Indeglia A, Foster M, Casey K, Leung J, Modarai SR, Leu JI, Duong B, Mes-Masson AM, Sims-Mourtada J, Auslander N, Drapkin R, Bitler BG, Zhang N, Murphy ME. Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer. Genes Dev. 2026 02 02; 40(3-4):199-214.
-
Kong T, Mabry A, Highkin M, Wang AZ, Hoog J, Guo Z, Gonzales-Gonzales A, Thomas S, Song Y, Gao F, Opyrchal M, Peterson L, Ademuyiwa F, Margenthaler J, Aft R, Glover-Collins K, Nehring L, Tao Y, Sanati S, Hagemann IS, Boulos F, Holt M, Ding L, Zhu W, Oh ST, Wang J, Witkiewicz AK, Knudsen ES, Bose R, Weber JD, Goetz M, Northfelt D, Luo J, Ma CX. Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. Nat Commun. 2026 Jan 27; 17(1):949.
-
Clayfield L, Malik D, Whittle J, Xu J, Mevel R, Fadlullah MZH, Patel R, Szpakowska M, Maqbool MA, Jones M, Lie-A-Ling M, Chevigne A, Paggetti J, Moussay E, Baker SM, Iqbal M, Maire P, Somervaille TCP, Ford HL, Kouskoff V, Largeot A, Lacaud G. Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemia. Cell Rep. 2026 Feb 24; 45(2):116875.
-
Porter R, Bockorny B, Corr BR, Mahadevan D, Wilky BA, El-Khoueiry AB, Bullock AJ, Hafez N, Moser J, Martynova A, Stebbing J, Joshi B, Bourdelais S, Delepine C, Chand D, Wu W, Johnson B, Grossman JE, O'Day SJ, Matulonis UA, Gordon MS. Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer. J Immunother Cancer. 2025 Dec 23; 13(12).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|